logo-loader
RNS
viewEvgen Pharma PLC

SAS study clarification

/**/ h2{margin-right:0cm;margin-left:0cm;font-size:18.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .ag{size:595.0pt 842.0pt;margin:2.0cm 42.55pt 2.0cm 42.55pt;}div.ag{}p.bm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; margin-right: 8.4pt; text-align: center}span.bk{font-size:11.0pt;color:black}p.bn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif"; margin-right: 8.4pt; text-align: center}p.bo{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; margin-left: 18.0pt; text-align: center}span.bp{font-size: 11.0pt; font-weight: bold}p.bq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-right:8.4pt;text-align:justify;background: white}p.br{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.bs{font-size: 11.0pt; font-div: italic} span.bt{font-size: 11.0pt; font-div: italic}p.bu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold}span.bc{font-size:11.0pt}p.bv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";}table.bw{margin-left:-5.4pt;border-collapse:collapse}td.av{width:237.3pt;padding:0cm 5.4pt 0cm 5.4pt}p.bx{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;vertical-align: baseline}span.by{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.bz{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold} span.ca{font-size: 11.0pt;font-family:"Calibri","sans-serif"}span.cb{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.cc{font-size:11.0pt;font-family:"Calibri","sans-serif"}td.as{width:244.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.cd{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: right; vertical-align: baseline}span.ce{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-div: italic}span.cf{font-size:11.0pt;font-family: "Calibri","sans-serif"}p.cg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align: right}span.aq{font-size:11.0pt;color:black;background:white}span.ch{font-size:11.0pt;font-family: "Calibri","sans-serif"} span.ci{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.cj{font-size:11.0pt;color:black}span.ck{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.cl{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:.75pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify;vertical-align:baseline}span.cm{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.cn{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.co{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.cp{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.cq{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.aj{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black; background:white} span.ax{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cr{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:8.25pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify; vertical-align:baseline}span.cs{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black} /**/
RNS Number : 9987S
Evgen Pharma PLC
11 November 2019
 

Evgen Pharma plc

 ("Evgen Pharma" or the "Company")

 

SAS study clarification

 

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, provides the following clarification:

 

Further to this morning's earlier announcement, the Company can confirm that it remains well funded to pursue commercial opportunities for SFX-01 in oncology and other disease areas. Evgen is unlikely to pursue the subarachnoid haemorrhage opportunity given the data announced earlier today. The reference to a strategic review relates to the significance of these data on related neurological indications.  

 

 

Enquiries:

 

Evgen Pharma plc www.evgen.com 

via Walbrook 

Dr Stephen Franklin, CEO 


Richard Moulson, CFO 




finnCap www.finncap.com 

+44 (0) 20 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance) 


Alice Lane, Manasa Patil (ECM) 




WG Partners LLP 

+44 (0) 20 3705 9330 

Nigel Barnes / Claes Spång  




Walbrook PR 

+44 (0)20 7933 87870 or [email protected]

Paul McManus / Anna Dunphy 

+44 (0)7980 541 893 / +44 (0)7876 741 001 

 

 

About Evgen Pharma plc 

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

 

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

 

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

 

For further information, please visit: www.evgen.com 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEAAFFFEPNFFF

Quick facts: Evgen Pharma PLC

Price: 7.45

Market: AIM
Market Cap: £9.88 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE